Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

[1]  J. Verweij,et al.  Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Bent,et al.  Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule , 1994, European journal of neurology.

[3]  W. Scheithauer,et al.  Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer , 1994, Cancer.

[4]  C. Boni,et al.  Cisplatin and etoposide in advanced colorectal carcinoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  G. Blijham.  Chemotherapy of colorectal cancer. , 1991, Anti-cancer drugs.

[6]  D. Johnson,et al.  Chronic daily administration of oral etoposide. , 1990, Seminars in oncology.

[7]  B. Redman,et al.  Low‐Dose Continuous Infusion 5‐Fluorouracil and Cisplatin: Phase II Evaluation in Advanced Colorectal Carcinoma , 1989, American journal of clinical oncology.

[8]  R. Labianca,et al.  Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. , 1988, European journal of cancer & clinical oncology.

[9]  P. Loehrer,et al.  A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Sabbath,et al.  Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma. , 1987, Cancer treatment reports.

[11]  A. Bartolucci,et al.  High-dose cisplatin in the treatment of advanced adenocarcinoma of the colon and rectum: a Southeastern Cancer Study Group trial. , 1986, Cancer treatment reports.

[12]  P. Lavin,et al.  Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275). , 1979, Cancer treatment reports.

[13]  R. Hahn,et al.  Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. , 1976, Cancer treatment reports.